3C
EPZM

361 Capital’s Epizyme, Inc EPZM Stock Holding History

361 Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$607K Buy
+37,784
New +$660K 0.28% 195

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

361 Capital's EPZM Position: Q2 2020 in Review

361 Capital opened a new position in Epizyme, Inc (EPZM) in Q2 2020: 37,784 shares worth $607K. The stake represents 0.28% of the portfolio and ranks #195 among its holdings.

160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • 361 Capital held 37,784 shares of Epizyme, Inc worth $607K as of Q2 2020.
  • Epizyme, Inc was a new 361 Capital position in Q2 2020.
  • Epizyme, Inc made up 0.28% of 361 Capital's portfolio in Q2 2020, its #195 holding.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.